Navigation Links
Research shows how 'Mallard' dye fills need for speed
Date:2/14/2013

Scientists at the University of York have developed a new medical tool which could help surgeons carrying out complex procedures in the operating theatre.

Researchers have developed a dye which provides a quick and accurate method of checking heparin levels in the blood. Heparin is an important anti-coagulant which has a significant role in major surgery. The scientists in the Department of Chemistry at York have used inspiration from biological systems to allow the dye to bind heparin even in highly competitive human serum.

In the laboratory, they have modified existing dyes which previously could not bind with heparin successfully under these challenging conditions. The modified dye, which has excellent sensing capacity for heparin pinpoints the anti-coagulant's level in human serum and has the potential to work more quickly than existing clinical methods for doing this.

The research, which was funded by the Biotechnology and Biological Sciences Research Council, is published in the Journal of the American Chemical Society.

Because the dye can rapidly detect heparin levels, the scientists have named it 'Mallard Blue'. It is the same shade as the livery of the A4 Pacific Mallard, which holds the world speed record for a steam locomotive, and is now preserved at the National Railway Museum in York.

Professor Dave Smith, of the Department of Chemistry at York who led the research said: "Our new dye allows the quantification of heparin in serum at clinically relevant levels and is the best in class for this application in terms of its ability to bind heparin strongly under really competitive biological conditions, and may improve on the currently used systems.

"We have named the dye 'Mallard Blue', after the record-breaking steam train, 'Mallard' which is housed in the railway museum here at York. Our dye is the same colour as the locomotive, and we believe it is similarly ground-breaking in its performance."

The York researc
'/>"/>

Contact: David Garner
david.garner@york.ac.uk
44-019-043-22153
University of York
Source:Eurekalert

Page: 1 2

Related biology news :

1. Researchers make racehorses fertile
2. Canadas aquatic ecosystems research gets boost from NSERC
3. FASEB joins President Obama in urging Congress to sustain investments in research and innovation
4. World first for fly research
5. Research improving breast cancer treatment by targeting tumor initiating cells
6. Explosive breakthrough in research on molecular recognition
7. Cities can reduce greenhouse gas emissions by 70 percent, says U of T researcher
8. USC researchers find possible genetic clues to organ development, birth defects
9. Researchers discover Achilles heel for lymphoid leukemia
10. Researchers find Asian needle ants displacing other aggressive invaders
11. NIH grant funds Boston College research into illnesses afflicting people living with HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
(Date:5/11/2015)... 2015 Curemark LLC, a privately held drug ... new Phase III double blind, randomized, placebo-controlled clinical trial ... on all children ages 3-8 with Autism. Previously, Curemark ... double blinded clinical trial for CM-AT in children ages ... digestive enzyme chymotrypsin. This new trial will help determine ...
(Date:5/7/2015)... May 7, 2015 Fingerprint ... FPC1022 and FPC1035, FPC,s smallest touch fingerprint sensors ... mainly considered for integration on the backside of ... OEMs increased possibilities to integrate touch fingerprint sensors ... also improves possibilities for module manufacturers to customize ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... Associate Professor Catherine Pickering, said the Griffith study looked ... can be dispersed through horse manure. The findings have ... Restoration . "We reviewed 15 studies on seed ... North America, three from Australia and one study each ...
... , Nov. 7, 2013  KaloBios Pharmaceuticals, Inc. (Nasdaq: ... its ongoing Phase 1 trial of KB004, an anti-EphA3 ... session at the 55 th American Society of ... trial of KB004 is a multi-center, dose-escalation study evaluating ...
... 7, 2013 The knowledge and skills required to change ... to those living with financial limitations. Competing demands on ... better diets. However, two researchers at the University ... the effects that three educational sessions might have on ...
Cached Biology News:Saddling up against the threat to our National Parks 2KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 2KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 3KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 4KaloBios to Present KB004 Interim Phase 1 Clinical Data in Hematologic Malignancies at ASH 53 'hands on' nutrition classes -- Enough to impact health behaviors in lower income women 2
(Date:5/21/2015)... 21, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or ... that develops and commercializes proprietary technologies and products for ... results for the second fiscal quarter ended March 31, ... continued to advance business with our existing customers and ... President and CEO of SQI. "The delivery of a ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 uBiome, ... announced a partnership with PicnicHealth, a healthcare company ... Participants diagnosed with Inflammatory Bowel Disease (IBD) will ... a complementary uBiome research kit. Both companies were ... , For more information on this ...
(Date:5/21/2015)... 21, 2015  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced positive updated results from ... for the treatment of unresectable glioblastoma multiforme (GBM), ... multisite trial is designed to investigate the preliminary ... tumors have progressed following prior treatment with surgery, ...
(Date:5/21/2015)... 2015 Tunnell Consulting, Inc. ... as senior statistician and Principal, a position to which ... the management and analysis of complex and large data ... , “We’re delighted to have Julia join the Tunnell ... said Dr. Philippe Cini, Group Vice President and leader ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... Oct. 12 Spherix Incorporated (Nasdaq: SPEX ... metabolic syndrome and atherosclerosis; and providers of technical and ... companies, today announced the close of previously reported agreements ... B Convertible Preferred Stock and warrants to purchase shares ...
... 12 US Oncology, Inc., the nation,s ... enrolled the 1,000th patient in a Phase I clinical ... Phase I clinical trials present special challenges, including increased ... trial designs, and some first-in-human trials, making Phase I ...
... SCOTTSDALE, AZ, Oct. 12 /PRNewswire/ - Dynamic Ventures ... the Editorial Board of Standard and Poor,s ("S&P") ... Records Market Access Program. Standard & Poor,s Corporation ... on U.S. and international public companies by investors ...
Cached Biology Technology:Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 2Spherix Announces Closing of Institutional Investors Purchase of $5.25 Million of Convertible Preferred Stock and Warrants 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 2US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 3US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 4US Oncology Network Recruits 1,000th Patient to Phase I Oncology Trials 5Dynamic Ventures Corporation's Information To Be Available Through Standard & Poor's Market Access Program 2
... Dawbarn and S.J. Allen (1995) ... by world authorities on current issues relating ... disease. Several major advances have been made ... this disease. Topics include molecular neuropathology through ...
Normal human serum, single donor...
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
biotin-4-fluorescein...
Biology Products: